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Introduction: Sarcoidosis is a multi-systemic granulomatous disorder 
characterized by multiple non-caseating granulomas involving intra-thoracic lymph 
nodes and lung parenchyma. Recently, the use of anti-tumor necrosis factor alpha 
(anti-TNFα) agents has been introduced for therapy of chronic and refractory 
sarcoidosis with controversial results. Infliximab (Remicade®) is a chimeric 
monoclonal antibody (mAb) that recognizes and binds TNFα, neutralizing its 
biological effects. In the present study, 99mTc labelled infliximab was used to study 
the expression TNFα in sarcoid lesions and to evaluate its role as a predictive 
marker of response to therapy with Remicade®.  
Material and Methods: A total of 10 patients with newly diagnosed sarcoidosis 
were enrolled together with 10 control patients affected by rheumatoid arthritis. All 
patients were studied by planar imaging of the chest with 99mTc-infliximab at 6 and 
24 h and total body [18F]-FDG PET/CT. Regions of interest were drawn over the 
lungs and the right arm and target-to-background ratios were analysed for 99mTc-
infliximab. SUVmean and SUVmax were calculated over lungs for FDG.  
Results and Discussion: Image analysis showed low correlation between T/B 
ratios and BAL results in patients despite positivity at [18F]-FDG-PET.  
Conclusion: In conclusion, patients with newly diagnosed pulmonary sarcoidosis, 







Sarcoidosis is a multi-systemic granulomatous disorder characterized by multiple 
non-caseating granulomas involving intra-thoracic lymph nodes and lung 
parenchyma. Inflammatory lesions can occur also in other organs like eyes and 
skin and, although less frequently, also in liver, spleen, extra-thoracic lymph 
nodes, salivary glands, heart, nervous system, bones and muscles. Even if its 
aetiology is still unknown, the role of cell-mediated immunity in the formation and 
in the maintenance of typical granulomas has been clarified [1, 2]. For this reason 
immunosuppressive therapy remains the gold standard for treatment and in 
particular with corticosteroid that is the first therapy line [3]. However, serious side 
effects of steroid therapy and the loss of long-term efficacy of this treatment have 
led researchers to use new drugs. Recently, the use of anti-tumor necrosis factor 
alpha (anti-TNFα) agents has been introduced for therapy of chronic and refractory 
sarcoidosis [4-6]. TNFα is an important cytokine released by alveolar activated 
macrophages, implicated in the development of granulomas. Infliximab 
(Remicade®) is a chimeric monoclonal antibody (mAb) that recognizes and binds 
TNFα, neutralizing its biological effects [7]. However, the effectiveness of such 
therapy is still uncertain and under investigation [8]. It is indeed not well known if 
TNFα is sufficiently present in sarcoid lesions to play a relevant biological role 
despite its presence in BAL has been shown to correlate with the severity of 




TNFα and may respond to anti-TNFα therapy, is difficult to ascertain. In this view, 
the assessment of TNFα in sarcoid lesions by a non-invasive technique could be 
important to strengthen the hypothesis behind the use of anti-TNFα drugs and to 
select patients possibly responders to anti-TNFα drugs. Currently there are no 
specific diagnostic tools to directly evaluate the presence of anti-TNF-α in sarcoid 
lesions but several methods have been reported for measuring disease activity. 
Chest X-ray and pulmonary function tests (spirometry), the measurement of serum 
angiotensin-converting-enzyme (ACE) levels and 67Ga-citrate scintigraphy, 
bronchoalveolar lavage (BAL) with evaluation of CD4+ and CD8+ lymphocytes, 
have all been used, and still are, as surrogate markers of diseases activity [10, 11]. 
In particular, [18F]-Fluoro-2-deoxy-D-glucose PET/CT ([18F]-FDG PET/CT) has 
been shown to be of high clinical value for evaluation of disease activity and extent 
and for therapy follow-up [12-15]. In the present study, we have used 
99mTechnetium (99mTc) labelled infliximab in patients with newly diagnosed 
sarcoidosis for non-invasive in vivo scintigraphic evaluation of the presence of 
TNFα in pulmonary and lymph nodal sarcoid lesions. Patients were also studied by 
[18F]-FDG PET/CT and BAL with lymphocyte phenotyping for complete 








PATIENTS AND METHODS 
 
Patients and diagnosis 
Study design included 20 patients with newly diagnosed sarcoidosis at stage II-III 
to be prospectively recruited for [18F]-FDG-PET/CT and 99mTc-infliximab 
scintigraphy and 10 control subjects (patients without sarcoidosis, but affected by 
rheumatoid arthritis (RA) to evaluate disease activity in joints). After enrolling all 
controls (7 females and 3 males, mean age 54+10 years) and 10 sarcoidosis 
patients, (8 females and 2 males, mean age 55+8 years) we performed an interim 
analysis and decided to stop recruitment, based on results. Sarcoidosis patients 
were symptomatic and presented respiratory symptoms of the disease; no one had 
involvement of specific organ but lungs, thoracic and extra-thoracic lymph nodes. 
They were also subjected to a standard assessment that included history and 
physical examination, with particular attention to respiratory disorders, blood test 
with peripheral blood counts and lymphocytes count ratio, X-ray examination of 
the chest, including X-ray and high resolution CT, bronchoscopy with 
bronchoalveolar lavage and bronchial biopsy, analysis of BAL with lymphocytes 
immune-phenotyping (2 patients refused to perform the BAL). The diagnosis of 
sarcoidosis was performed using histological demonstration of the presence of the 
typical non-caseating granulomas; others diseases such as Wegener’s 
granulomatosis, tuberculosis, aspergillosis and neoplastic diseases were excluded 




corticosteroid therapy or immunosuppressive drugs. The study was approved by 




Within 2 months from clinical diagnosis of sarcoidosis, a [18F]-FDG-PET/CT was 
performed after fasting for at least 6 h before the intravenous injection of [18F]-
FDG and with a serum glucose level lower than 160 mg/dl. Diazepam (5 mg) was 
administered to reduce muscle activity and activation of the brown fat. The activity 
of [18F]-FDG to be administered was calculated for each patient according to the 
following formula [(weight in Kg/10 x 37 MBq) +1]. The PET scan was performed 
with hybrid PET/CT Gemini, (Philips, NL). Imaging acquisition started 60 minutes 
after the radiopharmaceutical injection from the upper thigh to the head, with a 
preliminary low-dose unenhanced CT scan (16 slice, 100 mAs) followed by PET 
imaging  (2.5 min per bed position, 3D mode, matrix). Images were reconstructed 
with CT data by common iterative algorithm (OSEM, ordered subset expectation 
maximization, 2 iterations, 28 subsets) to obtain attenuation corrected images and 
anatomical mapping on functional images. [18F]-FDG-PET/CT images were 
visually analysed and disease activity was assessed separately in the mediastinum, 
hilum, lung parenchyma, extra-pulmonary lymph nodes, even with obvious 
evaluation of liver, spleen, bone marrow, bones and joint, in order to highlight a 




negative (positive = 18F-FDG uptake higher than background; negative = [18F]-
FDG uptake lower or equal to background). The semi-quantitative analysis was 
based on the analysis of standardized uptake value (SUV) evaluated as SUVmax and 
SUVmean, obtained by drawing regions of interest (ROIs) on trans-axial sections of 
lung parenchyma at the level of 3rd, 5th and 7th thoracic vertebral body. The SUV 
values obtained were then compared with those obtained in the control population. 
 
99mTc-infliximab scintigraphy 
The mAb infliximab was radiolabelled as previously described [16]. Briefly, 200 
µl of 99mTcO4-  (666 MBq) were added to 200 µl of reduced mAb (200 mg/ml) 
followed by 7 µl of methylene diphosponate (MDP). After 10 minutes of 
incubation at room temperature, quality controls were performed by instant thin 
layer chromatography (ITLC). Silica gel strips and 0.9% NaCl solution were used 
respectively as stationary and mobile phase for labelling efficiency determination. 
Albumin pre-coated silica gel strips and H2O:EtOH:NH3 (5:3:1) solution were used 
for colloids evaluation. Within 1 week from the PET/CT scan, all patients 
performed a scintigraphic study with radiolabelled anti-TNF-α after intravenous 
injection of 370 MBq of 99mTc-infliximab. Whole body images and planar static 
images of chest were acquired at 6 and 24 h post-injection with a large field of 
view, two head, gamma camera (Sky Light, Philips, NL), equipped with low-
energy high-resolution collimators and 20% energy windows centred at 140 KeV. 




h and 5 cm/min at 24 h taking in account the decay of the radionuclide. Anterior 
and posterior thorax images (matrix 256x256) were acquired for 300 seconds at 6 h 
and 600 seconds at 24 h). 
The results of scintigraphic studies were qualitatively analysed to identify any 
labelled mAb uptake and were visually compared with the pathological findings on 
PET images.  A semi-quantitative analysis was performed drawing ROIs over each 
lung parenchyma (ROIlung) including hilum, but excluding heart and spine, and a 
ROI over the upper right arm (ROIarm) as background, excluding joints. The counts 
were normalized by area and the target-to-background (T/B) ratio (ROIlung/ROIarm) 
was calculated at 6 h and 24 h for each lung in anterior and in posterior views. The 
average value of anterior and posterior values was considered for each patient. 
Results were compared with control subjects that underwent 99mTc-infliximab for 
RA and therefore considered “pulmonary negative”. 
 
Statistical analysis 
For each patient the average values of SUVmax and SUVmean, obtained in lung 
parenchyma, were calculated both in sarcoidosis patients and controls, obtaining 
for each group the mean value ± SD. Similarly, the mean values ± SD of T/B ratios 
in sarcoidosis patients and control group were calculated at each time point (6 and 
24 h). In sarcoidosis population correlations were made between mean SUV values 
and mean T/B ratio, mean SUV values and lymphocytes immune-phenotyping on 




assess the diagnostic accuracy of each methodology to evaluate disease activity. 
Students’ t test was applied to assess the significance of relationship between the 





The qualitative analysis performed on PET/CT studies in lungs showed complete 
agreement with the staging previously made by pulmonologists according to 
radiological and biochemical findings (Figure 1). Furthermore, in 3/10 patients 
PET showed other extra-pulmonary sites of disease, with involvement of axillary 
and abdominal-pelvic lymph nodes, not previously known, demonstrating its high 
sensitivity. The mean values ± SD of SUVmax obtained in patients with sarcoidosis 
were 4.43 ± 3.20 whereas in control subjects mean values ± SD of SUVmax were 
1.18 ± 0.20 (p < 0.001). These data are an expression of inflammation involvement 
of lung parenchyma in patients with sarcoidosis. The values of SUVmax and 
SUVmean correlated perfectly; therefore for subsequent analysis only SUVmax will 
be reported even if also SUVmean has always been considered. Despite the higher 
values of SUVmax in patients with sarcoidosis respect to controls, it was not 
possible to find a cut-off value above which to correlate the extent of uptake in the 
lung parenchyma with the degree of alveolitis. It was not also possible to obtain a 




(with particular reference to CD4+/CD8+ ratio) and the SUVmax values of patients 
with sarcoidosis. No correlation was also observed between SUVmax or SUVmean 
values and the CD4+/CD8+ ratio in blood. 
 
99mTc-infliximab scintigraphy 
The qualitative analysis of scintigraphy with 99mTc-infliximab showed no 
pathological focal accumulation of the labeled antibody (table 1). Both images at 6 
h, characterized by high vascular activity, and images at 24 h did not show the 
same pathological uptakes highlighted in the preliminary PET study (Figure 1 and 
2). The pulmonary distribution of the two radiopharmaceuticals was different, 
being predominantly diffused in the case of 99mTc-infliximab and rather focal with 
hileal involvement in the PET scans. 
Comparing T/B ratios on 99mTc-infliximab scintigraphy at 6 and 24 h, with SUVmax 
values of pulmonary uptake of FDG, no significant correlation was observed 
between these parameters. In only three patients was present a detectable diffuse 
bilateral lung uptake of anti-TNF-α at 6 h and 24 h on scintigraphic images, which 
could indicate increased levels of TNF-α in lung parenchyma of these patients. 
When we compared the mean values of lung uptake of labelled anti-TNF-α mAb in 
sarcoidosis patients and control subjects we found significant differences at 6 h 
(4.28 + 0.57 vs 3.2 + 0.74; patients vs controls; p = 0.002) but not at 24 h (3.15 + 
0.45 vs 2.7 + 0.65; patients vs controls; p = 0.057). A moderate correlation was 




T/B ratio at 6 h (Figure 3) but no correlation was found between average value of 





In the last decade, systemic autoimmune disease therapy has been revolutionized 
by the availability of biological drugs, or monoclonal antibodies, directed against a 
specific target implicated in the pathogenesis of disease. In patients with active 
sarcoidosis, the release of TNFα by activated alveolar macrophages has been 
widely documented in a lot of previous studies [17-21]. Infliximab (Remicade ®) 
is a chimeric monoclonal antibody of the type IgG1κ, with a variable region 
derived from murine anti-human TNFα and a constant sequence of human-derived 
IgG1. It was one of the first biological drugs to be used for the treatment of 
patients with sarcoidosis refractory to conventional therapy [22-26]. In particular, 
the multicenter phase II study of Baughman et al. [27] showed that in patients with 
sarcoidosis, symptomatic, refractory to corticosteroid therapy, treated with 
infliximab, there is a significant improvement of the forced vital capacity (FVC) 
without significant side effects related to the use of the drug. However, Panzelinas 
et al. [28] showed in a retrospective study, that in the majority of patients treated 
with infliximab, there was a recurrence of the disease about 3 months after 




extremely expensive, it would be desirable to be able to accurately select patients 
who really might benefit from this type of therapies. To date, however, there are no 
diagnostic markers for therapy decision making.  In order to answer this question, 
we undertook a study to assess whether scintigraphy with 99mTc-infliximab, 
showing directly the presence of TNFα in the lesions, may represent a marker for 
predicting the efficacy of biological therapy with anti-TNFα and then select the 
patients suitable for this type of treatment [29, 30]. Infliximab was labelled with 
high labelling efficiency, high specific activity and stability. Preliminary studies in 
vitro, in animals and humans have shown its usefulness in the evaluation of 
patients with Crohn's disease and rheumatoid arthritis [31-33]. [18F]-FDG-PET has 
proven to be a very sensitive method in the evaluation of disease activity. Many 
studies have shown its higher sensitivity compared to 67Gallium-citrate 
scintigraphy in the evaluation of disease and follow-up of therapy [34-41]. 
However, [18F]-FDG-PET lacks specificity and cannot be used for the selection of 
patients to be treated with anti-TNFα. Its main role remains the diagnostic 









Fig. 1.  99mTc-Infliximab scintigraphy of a sarcoidosis patient (patient 3/F) acquired at 6 h (anterior 
and posterior views, a) and at 24 h (anterior and posterior views, b) showing a moderate and diffuse 
uptake in the lung parenchima. [18F]-FDG-PET/CT images of the same patient showing a focal/hyleal 









Fig. 2.  99mTc-Infliximab scintigraphy of a sarcoidosis patient (patient 4/F) acquired at 6 h (anterior 
and posterior views, a) and at 24 h (anterior and posterior views, b) showing a moderate and diffuse 
uptake in the lung parenchima. [18F]-FDG-PET/CT images of the same patient showing a focal/hyleal 








Fig. 3.  Correlation between lung uptake of 99mTc-Infliximab at 6 h (T/B ratio) and CD4+/CD8+ ratio 




Fig. 4.  Correlation between lung uptake of 99mTc-Infliximab at 6 h (T/B ratio) and CD4+/CD8+ ratio 









































Summary of SUV obtained by FDG-PET/CT and T/B values (average of right and left lung 
calculated in anterior and posterior images) in patients with sarcoidosis. 
 
N°/SEX STAGE  SUVmax  SUVmean  T/B 6 h  T/B 24 h 
            
1/F I 1.91 0.54 4.16 2.84 
            
2/F II 3.47 0.99 4.34 2.75 
            
3/F II 4.38 2.19 3.52 3.49 
            
4/F II 2.64 0.79 4.82 3.97 
            
5/M I-II 3.05 1.02 3.61 3.14 
            
6/F II 5.28 1.25 4.77 3.24 
            
7/M I 2.23 0.73 4.14 2.72 
            
8/F II 12.87 4.55 4.73 3.41 
            
9/F II 3.01 0.88 3.43 2.49 
            
10/F II 5.48 0.90 4.73 3.42 
            
  
  
      
Mean+SD 4.43+3.2 1.38+1.2 4.22+0.55 3.15+0.45 
      
 
 
It is therefore right to compare the role of scintigraphy with 99mTc-infliximab in the 
evaluation of disease with the findings obtained with [18F]-FDG-PET, but mainly 
for the selection of patients suitable for treatment with unlabelled anti-TNFα mAb. 
From our data, although on a limited series, it appears that with a qualitative 




us to identify locations of extra-thoracic disease, like axillaries and abdomino-
pelvic lymph nodes. Inflammatory events in the lung parenchyma of sarcoidosis 
patients have been confirmed by higher SUVmax and SUVmean respect to normal 
subjects. The lack of correlation between the CD4+/CD8+ lymphocytes ratio in 
BAL and the values of both SUVmax and SUVmean in the lung, could be explained 
by the fact that the [18F]-FDG is taken up by various cell types involved in the 
inflammatory sarcoid granuloma, confirming its poor specificity. Alternatively 
BAL is performed in a single lung segment whereas SUV was calculated over the 
whole lungs. Scintigraphy with labelled anti-TNFα mAb was qualitatively positive 
in 4 out of 10 patients (both stage III), showing at 6 and 24 h a widespread uptake 
of the radiopharmaceutical in both lungs. The values of T/B ratio calculated, both 
on the 6 and 24 h images, did not correlate with the values of SUVmax and SUVmean 
calculated on ROIlung of PET.  There are many possible explanations for this 
different pattern of 18F-FDG and 99mTc-Infliximab in sarcoidosis patients. One of 
them is that the two radiopharmaceuticals show different aspects of the same 
phenomenon: the intense [18F]-FDG uptake by the cell populations responsible of 
alveolitis (macrophages, lymphocytes, etc.) and the presence of TNFα revealed by 
radiolabelled 99mTc-infliximab. Alternatively, there may be individual variability in 
the production of TNFα due to genetic reasons that depend on the stage of the 
disease.  
The lack of a clear focal uptake in some patients could also be caused by the long 




blood. This phenomenon is critical in highly perfused organs such as the lungs. In 
this case, the use of isotopes with longer half life, such as 89Zr and 111In, could help 
allowing to acquire imaging at later time points (e.g. 48 h or 72 h) thus improving 
T/B ratio due to clearance of radiopharmaceutical from the blood. Moreover, it 
should be kept in mind that contrarily to what happens in lesions where the targets 
of a radiopharmaceutical is a membrane bound receptors, TNFα is also a soluble 
molecule and a possible wash out or low concentration in the lesions could prevent 
the visualization of distinctive foci.  
Indeed, on the basis of the review of literature, the most responsive patients to 
therapy with infliximab appear to be those with extra-pulmonary disease, with 
involvement of skin, nervous system, bone and ocular disease; it would be 
interesting to study these patients with 99mTc-infliximab scintigraphy in order to 
effectively assess the presence of TNFα in other extra-pulmunary tissues affected 
by sarcoidosis.   
Our choice was to investigate patients with newly diagnosed sarcoidosis that did 
not undergo prior therapies, based on the need to study "naive" patients in which 
no previous immunosuppressive therapy was administered.  
Despite to what we expected the T/B ratio calculated at 6 and 24 h did not correlate 
with the amount of lymphocytes in BAL, indicating that not all immune-mediated 








Labelled anti-TNFα mAb scintigraphy could be a good tool for the selection of 
patients to be treated with anti-TNFα drugs, however, in our study most of the 
examined patients showed a negative 99mTc-infliximab scintigraphy, underlining a 
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